What is the outlook for the CSL (ASX:CSL) share price following FY21 results?

Where to now for CSL shares?

| More on:
Two children sit amid a tangle of wires at a desk looking sad and despondent.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is reacting poorly after the release of the medical giant's FY2021 earnings results this morning. At the time of writing, CSL shares are down 2.31% to $291.08 apiece after initially popping to $302.80 per share this morning. 

It seems investors don't really know what to make of CSL's earnings this morning.

As my Fool colleague James covered earlier today, CSL reported that revenues and net profits were both up year on year for FY21, by 9.6% and 10% respectively. This enabled CSL to boost its full-year dividend by a healthy 10% to US$2.22 a share. However, the healthcare company also gave a warning. It is expecting net profits to fall over the current FY2022 year by between 2.5% and 6.8%.

No wonder investor reaction was mixed.

So now that we know what CSL's books look like for FY2021, what is the outlook for the CSL share price now?

What the broker says about the CSL share price

Well, one broker who was paying attention to CSL's results this morning was investment bank, Goldman Sachs. In light of CSL's earnings, Goldman has retained a neutral rating on CSL, with a 12-month share price target of $305. That implies a potential upside of just over 3% for the next 12 months (not including dividend returns).

Goldman noted that CSL's 10% growth metrics on both revenue and earnings are positive, in particular from CSL's Behring division. However, it also highlighted how the challenging conditions of the pandemic are clearly making it hard for CSL to give accurate guidance for the year ahead. Goldman also pointed to how CSL's management has traditionally been conservative with its guidance, but that "the current conditions are clearly unprecedented".

Going forward, Goldman sees further disruptions to CSL's plasma collection business, the competitive threat of mRNA vaccines to the Seqirus division and plasma donor fee inflation as key risk areas to watch.

At the current CSL share price, the company has a market capitalisation of $135.6 billion, a price-to-earnings (P/E) ratio of 32.5 and a trailing dividend yield of 1%. CSL shares are currently up 3.6% year to date in 2021 so far, and a more modest 0.7% over the past 12 months.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »